2:00 Panel Discussion: Optimizing Imaging Endpoints, Mapping the Current Imaging Landscape & Emerging Tools in Neuroscience
Time: 2:00 pm
day: Conference Day 2
Details:
- Review of Current Imaging Modalities: Overview of PET, MRI, fMRI, and other techniques used in neurodegenerative disease trials (e.g., AD, PD, MS, ALS)
- Limitations of Imaging Biomarkers in Clinical Trials: Challenges including accessibility, cost, patient burden, and limitations in sensitivity or specificity
- Innovations on the Horizon: Discussion of emerging imaging techniques and tools, including novel radiotracers, high-resolution modalities, and multimodal approaches
- Integrating Imaging with Other Biomarker Modalities: How imaging can complement fluid biomarkers, digital measures, and omics data for a more holistic disease profile
- What regulatory criteria must be met for a surrogate endpoint to be accepted as a validated substitute for a clinical endpoint?
